Earle A. Chiles Research Institute
@ChilesResearch
Followers
2K
Following
6K
Media
827
Statuses
4K
The research division of Providence Cancer Institute Oregon and a Providence Center of Excellence for precision immuno-oncology and cellular therapy.
Portland, Oregon
Joined November 2012
RT @rbryanbell: @jitcancer vision: Opportunities for deeper understanding of anti-tumor activity, toxicity & resistance to optimize cance….
0
1
0
RT @FlavioRochaMD: Great to hear about the exciting developments in .TIL and CAR-T therapy for #cholangiocarcinoma. @surgeonsci @OHSUKnight….
0
5
0
RT @ACIR_org: Holay et al. engineered INBRX-106, an OX40 agonist composed of six binding domains fused to a human IgG1 Fc. .
0
1
0
RT @sitcancer: #SITC25 Science Preview: Join @BernardAFox @ChilesResearch, Christopher A. Klebanoff, MD @MSKCancerCenter, Rom S. Leidner, M….
0
1
0
RT @rbryanbell: Delighted to present path response from our Neoadjuvant ImmunoRadioTherapy (NIRT-2) trial in pts w HPV- HNSCC @ASCO.mPR=71%….
0
14
0
RT @PatrickHwuMD: Had a great time recording a new episode of #TheImmunoVerse podcast with @BernardAFox of @ChilesResearch today at #ASCO25….
0
7
0
RT @rbryanbell: Great to be @AHNSinfo Annual meeting. Watch for the Immunotherapy session on Wed in which @ChilesResearch IO Fellow Rob….
0
2
0
RT @ScienceTM: Instability in regulatory T cells may predict the efficacy of cancer #immunotherapy that combines anti-PD-1 and anti-LAG-3 a….
0
2
0
RT @BernardAFox: Dr Andy Weinberg @ChilesResearch & @agon_ox opens the #TVACT2025 at @UHCancerCenter #Honolulu - 30 yrs since 1st #TVACT199….
0
3
0
RT @rbryanbell: Excited to be in Chicago for the @AACR Annual Meeting & very am much looking forward to the Keynote 689 presentation by @Dr….
0
3
0
RT @ACIR_org: Rolig and Peng et al. identified mouse tumor models with high (LAG3hi) or low (LAG3lo) frequencies of LAG3+ lymphocytes. http….
0
1
0
The @AACR Annual Meeting is live, and we are thrilled to have members of our #FINISHCANCER team there to present their study findings! Find links to all our presentations on our blog #AACR25.
0
0
2
Join us at the @OncLive State of the Science Summit on April 17. Register at
The latest in breast cancer treatment—LIVE in Portland with @providence! 📢 Join us at the State of the Science Summit on April 17 with expert insights from David M. Page, MD, Evie A. Hobbs, MD, Brie Chun, MD, and Nathalie M. Johnson, MD. Register today:
0
0
0
RT @rbryanbell: 48-year-old colorectal cancer survivor urges people to screen early. On behalf of our entire @providence #FinishCancer Team….
0
1
0
2025 marks a big change for us as @rbryanbell begins his new leadership roles at PCI and @ChilesResearch. He stopped by @KATUNews to share his vision for the future of cancer care. Watch #FINISHCANCER #immunotherapy.
0
2
4
RT @oncodaily: Earle A. Chiles Research Institute’s tripling of response rates for patients with head and neck cancer – @BernardAFox (@Chil….
0
2
0
Wishing you a holiday season of peace, love, and meaningful moments with family and friends. From all of us at Providence Cancer Institute and Earle A. Chiles Research Institute, happy holidays and best wishes for the new year.
0
0
1
As we prepare to start a new year, we reflect on our commitment to advancing cancer care and research for the benefit of our patients and communities. Looking back, there’s much to celebrate and much more to look forward to. Read about our year:
0
0
2
Be sure to tune in to @KATUNews Afternoon Live today (12/9) at 2:00 p.m. as our @rbryanbell discusses his transition to executive medical director of Providence Cancer Institute and director of the @ChilesResearch. #FINISHCANCER
0
0
3
RT @ACIR_org: Fesneau et al. showed that in HNSCC and CRC tumors, expression of the inhibitor NKG2A, a receptor for HLA-E that is associate….
0
1
0